FDA Approved: YUPELRI — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved Viatris Specialty LLC's supplemental application for YUPELRI (revefenacin), expanding its approved labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Yupelri (revefenacin)

Snippet

SUPPL AP for YUPELRI (REVEFENACIN)